All In Biotech

Drug Trial Radar · NCT01257074

Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis

A Randomized, Double-Blind, to Compare Non-inferiority Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis.

Last checked: Nov 20, 2026Latest source record: Mar 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

76

Actual

Start

Feb 2012

Primary completion

Mar 2012

Study completion Oct 2012

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Dec 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Herpes labialis is the most common recurrent manifestation of herpes simplex. The purpose of this study is to check the non-inferiority efficacy and safety of penciclovir 10mg/g as treatment for Herpes Labialis in comparison to acyclovir 50mg/g.

Conditions

  • Herpes Labialis

Interventions

  • Acyclovir 50mg/gDrug

    Cream, dose 5 times daily during 5 days

  • Penciclovir 10mg/gDrug

    Cream, dose 5 times daily during 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy will be evaluated by the proportion of subjects with non herpes labialis manifestationTime frame: Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Flavia Addor

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.